Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY.

Autor:	Pinto, A. A., Bosch, F., Bisneto, J. C. Villasboas, Sanz, R. García, Garcia, C. Grande, Smith, S. D., Wallace, D. S., Arcaini, L., Merryman, R., Marolleau, J., De Filippi, R., Chêne, L., Bonny, C., Fagerberg, J., Friedberg, J. W., Ansel, S., Armand, P., Zinzani, P. L.
Předmět:	NON-Hodgkin's lymphoma RITUXIMAB LENALIDOMIDE B cell lymphoma MUCOSA-associated lymphoid tissue lymphoma BACTERIAL proteins
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p581-582, 2p
Abstrakt:	Expansion of specific CD8+ T cells against the mimic peptides and targeted B cell proteins was detected in 4/6 pts, including in 2 pts with no measurable B cells at baseline (prior anti-CD20). B Introduction: b T cells normally recognize bacterial proteins originating from the gut microbiome, including some that cross-react with normal host B cell-specific proteins. Memory CD8+ T cell clones can be detected in the peripheral blood of healthy donors recognizing the EO2463 mimic peptides; in vitro, such cells can kill target T2 cells loaded with mimic or human counterpart peptides. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text